{"id":785886,"date":"2023-09-25T09:12:56","date_gmt":"2023-09-25T13:12:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/"},"modified":"2023-09-25T09:12:56","modified_gmt":"2023-09-25T13:12:56","slug":"pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/","title":{"rendered":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:15pt\">\n          <strong>Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>PRINCETON, N.J., Sept.  25, 2023  (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company\u2019s proprietary T cell activating platforms, today announced that its Key Opinion Leader (KOL) Roundtable on Addressing Current and Future Treatments for Recurrent\/Metastatic Human Papillomavirus (HPV)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 \u2013 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023.<\/p>\n<p>The event will be moderated by PDS Biotech\u2019s Chief Medical Officer, Dr. Lauren V. Wood, and will feature presentations from the following head and neck cancer KOLs:<\/p>\n<ul type=\"disc\">\n<li>Dr. Glenn Hanna, Assistant Professor, Harvard University and Medical Oncologist, Dana-Farber Cancer Institute<\/li>\n<li>Dr. John Kaczmar, Associate Professor, Medical University of South Carolina<\/li>\n<li>Dr. Ricard Mes\u00eda, Head of Medical Oncology, Catalan Institute of Oncology<\/li>\n<li>Dr. Katharine Price, Associate Professor, Oncology Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center<\/li>\n<\/ul>\n<p>Registration for the event is open. A live webcast of the event will be available online in the Investor Relations section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CbwbIIzCS-KN0JOd3MMzKDKi_q5iUkSRf6uxNocGLSOLAFncr3Kq-JssRYhu-aQlPVI86KoARwYCaYchPLhnkFG93UiaE9VcvvSM4_DgwWKytkcuWBuHpwUiRC7x94PWVncGj_gEe3BaP_yDMTtpLp9hcoSlAm8EtgKgqFjDla4=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.pdsbiotech.com\/index.php\/investors<\/a>. A replay will be available for 90 days following the webcast.<\/p>\n<p>\n        <strong>About PDS Biotechnology<\/strong><br \/>\n        <br \/>PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune<sup>\u00ae<\/sup>, Versamune<sup>\u00ae<\/sup> plus PDS0301, and Infectimune<sup>\u00ae<\/sup> T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune\u00ae clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA<sup>\u00ae<\/sup> for the treatment of recurrent\/metastatic HPV16-positive head and neck cancer in 2023. Our Infectimune<sup>\u00ae<\/sup> based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B0qAcJ-4HNrpC4aWz2yEyTV5UM85W_Ozs6xnU9MVCkc_93IjLFYNykF-4EMMLdM5amaOnklaMm3aiBte3qPfH8c-blScKVKpnv-Gg0Qs9x2TaXBYjr0N-8UJEkbkP07wIvWoqKFmMm2ntJarMcrGaBO7DWi8fR4PEIKchn_FmypM2hUIa3sXnqzozf0YWQQHQ4bA5pmMIzkkVc9JWNAVNbKgakhKEQWLwKzKkmrWayvxtZ8lsLVdTQxUYQpJ_QdwcX9kTrOOhArGcjgYsG1KmvQ69b1Rc2t-GXZ9E0IdVUSEm5f5nN3A_wI4-16wDhDbmZKFB9qnq6HUAf620QY2Z5KJ1-hgktPpY09cqn7oiSwZxSTSIlCUApy6dtdb08kuzc_okMAfXAf9PI6gRZWOvhlTOYTg1joZz4OGh8X8jHDta1rzVoBaoFhQSZGVbN6qVWS6hmoVaUIFaXH6zrzjn8zGDf8o_oo-1qF7ktRUzO0=\" rel=\"nofollow noopener\" target=\"_blank\">www.pdsbiotech.com<\/a> or follow us on Twitter at @PDSBiotech.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the \u201cCompany\u201d) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company\u2019s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast,\u201d \u201cguidance\u201d, \u201coutlook\u201d and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company\u2019s ability to protect its intellectual property rights; the Company\u2019s anticipated capital requirements, including the Company\u2019s anticipated cash runway and the Company\u2019s current expectations regarding its plans for future equity financings; the Company\u2019s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company\u2019s operations or require the Company to relinquish rights to the Company\u2019s technologies or product candidates; the Company\u2019s limited operating history in the Company\u2019s current line of business, which makes it difficult to evaluate the Company\u2019s prospects, the Company\u2019s business plan or the likelihood of the Company\u2019s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune<sup>\u00ae<\/sup> and Infectimune<sup>\u00ae<\/sup> based product candidates; the future success of such trials; the successful implementation of the Company\u2019s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune<sup>\u00ae<\/sup> and Infectimune<sup>\u00ae<\/sup> based product candidates and the Company\u2019s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company\u2019s product candidates; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company\u2019s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.\u202f<\/p>\n<p>Versamune<sup>\u00ae<\/sup> and Infectimune<sup>\u00ae<\/sup> are registered trademarks of PDS Biotechnology Corporation. KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, N.J., USA.<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong><br \/>\n        <br \/>Deanne Randolph<br \/>PDS Biotech<br \/>Phone: +1 (908) 517-3613<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=19pKLuu9ETDS7FPBLGVQxiqWFjsYRxz362uoN8noLYK97VLuZHdX7CqVBRnH7H7mgo4rkKOYVCQbdakYT19aNrVq6gNG0-Jnk2ZptRS_ol4=\" rel=\"nofollow noopener\" target=\"_blank\">drandolph@pdsbiotech.com<\/a><\/p>\n<p>Rich Cockrell<br \/>CG Capital<br \/>Phone: +1 (404) 736-3838<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H8INsjn2a-_zVLbW2w4xOEMxxPnYF65vNirvqFfKSWkeI3BO0ZEpov5ok2FPxPmh7Sk3KiC6zJH6VeQkcZ-sOQ==\" rel=\"nofollow noopener\" target=\"_blank\">pdsb@cg.capital<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Gina Cestari<br \/>6 Degrees<br \/>Phone: +1 (917) 797-7904<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uE9ovPqbT-cYnV_qK-GJyT1YFIrkczix8phWpzGegYbqz8cSErf2ZP4kOaeMkoYwZJ32JnorJLrEB30toUYMqvLpGlpUE9pbQjEJbXFrYaU=\" rel=\"nofollow noopener\" target=\"_blank\">gcestari@6degreespr.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTk3NDg1ZjMtYzQ0ZC00YjAzLWIzMTMtMWFmMDdlOTc2MTVkLTEwMjg3NjE=\/tiny\/PDS-Biotechnology-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company\u2019s proprietary T cell activating platforms, today announced that its Key Opinion Leader (KOL) Roundtable on Addressing Current and Future Treatments for Recurrent\/Metastatic Human Papillomavirus (HPV)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 \u2013 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company\u2019s proprietary T cell activating platforms, today announced that its Key Opinion Leader (KOL) Roundtable on Addressing Current and Future Treatments for Recurrent\/Metastatic Human Papillomavirus (HPV)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 \u2013 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023. &hellip; Continue reading &quot;PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T13:12:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\\\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101\",\"datePublished\":\"2023-09-25T13:12:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/\"},\"wordCount\":1172,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/\",\"name\":\"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\\\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\",\"datePublished\":\"2023-09-25T13:12:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\\\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk","og_description":"Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company\u2019s proprietary T cell activating platforms, today announced that its Key Opinion Leader (KOL) Roundtable on Addressing Current and Future Treatments for Recurrent\/Metastatic Human Papillomavirus (HPV)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 \u2013 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023. &hellip; Continue reading \"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-25T13:12:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101","datePublished":"2023-09-25T13:12:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/"},"wordCount":1172,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/","name":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=","datePublished":"2023-09-25T13:12:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzM1NCM1ODI5MDg4IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent\/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}